Source: Myriad Genetics Form 10-K, Fiscal Year 2025

Summary

Myriad Genetics' annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on 2026-02-24. Accession number 0000899923-26-000018; filer CIK 0000899923; IRS employer identification number 87-0494517.

This is the primary record for Myriad's revenue, losses, headcount, headquarters, and laboratory footprint. Anything on the venture page that a reader would act on — how big the company is, whether it is growing, where it actually sits in Salt Lake City — should trace here rather than to the company's marketing site.

The filing and its XBRL facts are retrievable indefinitely from EDGAR by CIK and accession number: https://data.sec.gov/submissions/CIK0000899923.json lists every filing, and https://data.sec.gov/api/xbrl/companyconcept/CIK0000899923/us-gaap/{tag}.json returns the tagged financial facts with their source accessions.

Useful Claims

• Total revenue for FY2025 was $824.5 million, down from $837.6 million in FY2024 (FY2023: $753.2 million).
• Net loss for FY2025 was $365.9 million, against a net loss of $127.3 million in FY2024; basic and diluted loss per share was $3.95.
• The FY2025 loss includes goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million, related to the Women's Health and Mental Health reporting units.
• Myriad had approximately 2,700 full-time equivalent employees as of December 31, 2025.
• Principal executive offices are at 322 North 2200 West, Salt Lake City, Utah 84116 — not the Research Park address carried by some third-party directories.
• The Salt Lake City corporate headquarters holds approximately 234,000 square feet of laboratory and office space; the lease runs to 2038 with renewal options.
• Laboratories in Salt Lake City, Utah; Mason, Ohio; and South San Francisco, California are CLIA certified to perform high-complexity tests.
• Myriad is a Delaware corporation (SIC 2835, in vitro and in vivo diagnostic substances).

Verbatim

"During the year ended December 31, 2025, we reported total revenue of $824.5 million, a net loss of $365.9 million, and basic and diluted loss per share of $3.95." — Item 7, Management's Discussion and Analysis

"Goodwill and long-lived asset impairment charges for the year ended December 31, 2025 included primarily goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million related to our Women's Health and Mental Health reporting units." — Item 7, Management's Discussion and Analysis

"As of December 31, 2025, we had approximately 2,700 full-time equivalent employees." — Item 1, Business (Human Capital)

"We are a Delaware corporation with our principal executive offices located at 322 North 2200 West, Salt Lake City, Utah 84116." — Item 1, Business (Available Information)

"Our corporate headquarters is located in West Salt Lake City, Utah, which has approximately 234,000 square feet of laboratory and office space." — Item 2, Properties

"The lease for our Salt Lake City facility has a remaining term of thirteen years, expiring in 2038, and provides for renewal options for up to ten additional years." — Item 2, Properties

"Our laboratories in Salt Lake City, Utah, Mason, Ohio, and South San Francisco, California are CLIA certified to perform high complexity tests." — Item 2, Properties

Multi-year figures as the SEC's own XBRL API returns them, from https://data.sec.gov/api/xbrl/companyconcept/CIK0000899923/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json and .../NetIncomeLoss.json (val in USD, accn is the filing that reported it):

2023-01-01..2023-12-31  revenue     753200000   accn 0000899923-26-000018
2024-01-01..2024-12-31  revenue     837600000   accn 0000899923-26-000018
2025-01-01..2025-12-31  revenue     824500000   accn 0000899923-26-000018
2023-01-01..2023-12-31  net income -263300000   accn 0000899923-26-000018
2024-01-01..2024-12-31  net income -127300000   accn 0000899923-26-000018
2025-01-01..2025-12-31  net income -365900000   accn 0000899923-26-000018

Reliability Notes

A Form 10-K is a primary-tier source: it is filed under securities-law accuracy duties, audited as to its financial statements, and archived permanently by the SEC. It is the highest-confidence source available for revenue, losses, headcount, and property, and it supersedes press coverage and the company's own website on all of those.

Two limits worth stating. First, a 10-K is a point-in-time document — the figures above describe FY2025 and were superseded for interim periods by the Q1 and Q2 2026 Form 10-Qs (the most recent, accession 0000899923-26-000072, covers the quarter ended 2026-06-30). Second, forward-looking statements in the filing are management's expectations, not facts, and carry the filing's own safe-harbor caveats.

Related Pages

• Myriad Genetics
• Myriad Genetics BRCA Sequencing and Testing